BUSINESS COMBINATIONS AND ACQUISITIONS (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended																							1 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Amortization of intangible asset	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Amortization of intangible asset	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Transaction costs	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Transaction costs	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Stock-based compensation expense related to the acceleration of vesting of previously unvested awards	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Stock-based compensation expense related to the acceleration of vesting of previously unvested awards	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Restructuring charges	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Restructuring charges	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Intercompany revenues related to the co-promotion DIFICID	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Intercompany revenues related to the co-promotion DIFICID	Dec. 31, 2013 Optimer Pharmaceuticals, Inc. Additional interest expense	Dec. 31, 2012 Optimer Pharmaceuticals, Inc. Additional interest expense	Dec. 31, 2013 Trius Therapeutics, Inc. Transaction costs	Dec. 31, 2012 Trius Therapeutics, Inc. Transaction costs	Dec. 31, 2013 Trius Therapeutics, Inc. Stock-based compensation expense related to the acceleration of vesting of previously unvested awards	Dec. 31, 2012 Trius Therapeutics, Inc. Stock-based compensation expense related to the acceleration of vesting of previously unvested awards	Dec. 31, 2013 Trius Therapeutics, Inc. Compensation expense related to severance and retention agreements and restructuring charges	Dec. 31, 2012 Trius Therapeutics, Inc. Compensation expense related to severance and retention agreements and restructuring charges	Dec. 31, 2013 Trius Therapeutics, Inc. Research and development	Dec. 31, 2012 Trius Therapeutics, Inc. Research and development	Dec. 31, 2011 Adolor Corporation	Dec. 31, 2011 Adolor Corporation Amortization of intangible asset	Dec. 31, 2011 Adolor Corporation Transaction costs	Dec. 31, 2011 Adolor Corporation Restructuring charges
Recurring and non-recurring adjustments to pro forma information
Net income	$ (6,006)	$ (33,895)	$ 15,242	$ 6,088	$ 37,837	$ 40,321	$ 43,123	$ 32,794	$ (18,571)	$ 154,075	$ 33,023	$ (35,600)	$ (44,000)	$ 34,300	$ (34,300)	$ 7,200	$ (7,200)	$ 21,600	$ (21,600)			$ (29,700)	$ (41,500)	$ 24,900	$ (24,900)	$ 22,700	$ (22,700)	$ 9,400	$ (9,400)	$ (4,100)	$ (15,100)		$ (20,200)	$ 13,100	$ 9,300
Revenues	$ 299,741	$ 265,993	$ 258,779	$ 229,929	$ 245,919	$ 238,181	$ 230,567	$ 211,692	$ 1,054,442	$ 926,359	$ 753,972									$ (12,300)	$ (23,200)											$ 2,600